Newbury Pharmaceuticals

Newbury expands its portfolio with two ready to launch products

Newbury Pharmaceuticals is pleased to announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in Sweden.

“I am pleased to announce the addition of two new products to our portfolio and in particular that these two products will be available for commercialization already in 2023.” Says Mr. Lars Minor, CEO of Newbury.

Both products are sourced from new partners to Newbury and based on a Distribution and Marketing agreement where Newbury will perform the commercialization in the territory.

Datum 2022-11-23, kl 09:30
Källa MFN
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.